Pau Terradas-Montana

Pau Terradas-Montana

Auto-generated profile, based on publicly available information

Pau Terradas-Montana

Novartis Farmaceutica, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2022 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
CSCristina Segú-Vergés
Cristina Segú-Vergés
JGJessica Gómez
Jessica Gómez
PTPau Terradas-Montana
Pau Terradas-Montana
LMLaura Artigas Matilla
Laura Artigas Matilla
SSSerge Smeets
Serge Smeets
SSSinisa Savic
Sinisa Savic
Chronic spontaneous urticaria (CSU) is a rare, heterogeneous, severely debilitating, and often poorly controlled skin disease resulting in an itchy eruption that can be persistent. Antihistamines and omalizumab, an anti-IgE mAb, are the only licensed therapies. Although CSU pathogenesis is not yet fully understood, mast cell activation through the IgE:high-affinity IgE receptor (FcεRI) axis appears central to the disease process. We sought to model CSU pathophysiology and identify in silico the mechanism of action of different CSU therapeutic strategies currently in use or under development. Therapeutic performance mapping system technology, based on systems biology and machine learning, was used to create a CSU interactome validated with gene expression data from patients with CSU and a CSU model that was used to evaluate CSU pathophysiology and the mechanism of action of different therapeutic strategies. Our models reflect the known role of mast cell activation as a central process of CSU pathophysiology, as well as recognized roles for different therapeutic strategies in this and other innate and adaptive immune processes. They also allow determining similarities and differences between them; anti-IgE and Bruton tyrosine kinase inhibitors play a more direct role in mast cell biology through abrogation of FcεRI signaling activity, whereas anti-interleukins and anti-Siglec-8 have a role in adaptive immunity modulation. In silico CSU models reproduced known CSU and therapeutic strategies features. Our results could help advance understanding of therapeutic mechanisms of action and further advance treatment research by patient profile.

24 May 2022 in Reumatología Clínica
Verified
Journal Article
Closed access
EMEugenio de Miguel
Eugenio de Miguel
CFCristina Fernández-Carballido
Cristina Fernández-Carballido
JGJ. Gratacós
J. Gratacós
JPJosé L. Pablos
José L. Pablos
XJXavier Juanola
Xavier Juanola
CSCarlos Sastré
Carlos Sastré

2 February 2023 in Reumatología Clínica (English Edition)
Verified
Journal Article
Closed access
EMEugenio de Miguel
Eugenio de Miguel
CFCristina Fernández-Carballido
Cristina Fernández-Carballido
JGJ. Gratacós
J. Gratacós
JPJosé L. Pablos
José L. Pablos
XJXavier Juanola
Xavier Juanola
CSCarlos Sastré
Carlos Sastré

13 April 2023 in Reumatología Clínica (English Edition)
Verified
Journal Article
Closed access
JGJordi Gratacós
Jordi Gratacós
JPJosé L. Pablos
José L. Pablos
EMEugenio de Miguel
Eugenio de Miguel
XJXavier Juanola
Xavier Juanola
CFCristina Fernández-Carballido
Cristina Fernández-Carballido
CSCristina Sanabra
Cristina Sanabra

21 June 2022 in Reumatología Clínica
Verified
Journal Article
Closed access
JGJordi Gratacós
Jordi Gratacós
JPJosé L. Pablos
José L. Pablos
EMEugenio de Miguel
Eugenio de Miguel
XJXavier Juanola
Xavier Juanola
CFCristina Fernández-Carballido
Cristina Fernández-Carballido
CSCristina Sanabra
Cristina Sanabra